Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes:

作者: N. Papanas , E. Maltezos

DOI: 10.4137/CMT.S1085

关键词: InsulinInternal medicineGlucose uptakeMetabolic disorderHeart failureType 2 diabetesBiomedical engineeringMedicineDiabetes mellitusInsulin resistanceMetformin

摘要: Metformin is now the most widely prescribed oral hypoglycemic agent. This review outlines its use in treatment of type 2 diabetes. The main mechanisms action include reduction appetite and intestinal carbohydrate absorption, inhibition hepatic gluconeogenesis, increased glucose uptake by peripheral tissues. has been established as drug choice for first-line According to broadly accepted guidelines, it should be administered early at diagnosis this metabolic disorder, alongside diet exercise. agent may also safely efficaciously combined with all other agents, enabling a useful additive effect. Additionally, conjunction insulin. combination aims offset insulin resistance, reduce requirements minimize weight gain. Of greater importance, metformin consistently shown have favorable effect on cardiovascular risk factors improve outcomes. Interestingly, efficacy accompanied excellent safety: caution only needed avoid patients obvious contraindications (mainly chronic renal failure, congestive heart obstructive pulmonary disease, liver disease). Moreover, cost-effectiveness established. Generally, an both specialized setting primary health care.

参考文章(123)
H. Wallberg-Henriksson, T. Sonnenfeld, A. Thorne, D. Galuska, J. Zierath, Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle. Diabète & métabolisme. ,vol. 17, pp. 159- 163 ,(1991)
Negah Rassouli, Neda Rasouli, Behzad Molavi, Suveer Bagwe, A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vascular Health and Risk Management. ,vol. 3, pp. 967- 973 ,(2007)
Gary N Fox, Metformin in type 2 diabetes. Journal of Family Practice. ,vol. 53, pp. 900- ,(2004)
GT Tucker, C Casey, PJ Phillips, H Connor, JD Ward, HF Woods, Metformin kinetics in healthy subjects and in patients with diabetes mellitus. British Journal of Clinical Pharmacology. ,vol. 12, pp. 235- 246 ,(1981) , 10.1111/J.1365-2125.1981.TB01206.X
Dale S Edgerton, KM Johnson, Alan D Cherrington, Current strategies for the inhibition of hepatic glucose production in type 2 diabetes Frontiers in Bioscience. ,vol. Volume, pp. 1169- 1181 ,(2009) , 10.2741/3301
R Moses, Repaglinide in combination therapy. Diabetes Nutrition & Metabolism. ,vol. 15, pp. 33- 38 ,(2002)
Shelley R Salpeter, Edwin E Salpeter, Elizabeth Greyber, Gary A Pasternak, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database of Systematic Reviews. ,vol. 2010, ,(2010) , 10.1002/14651858.CD002967.PUB4
Terri Poon, Patric Nelson, Larry Shen, Michael Mihm, Kristin Taylor, Mark Fineman, Dennis Kim, Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study Diabetes Technology & Therapeutics. ,vol. 7, pp. 467- 477 ,(2005) , 10.1089/DIA.2005.7.467
Louis Monnier, Emilie Mas, Christine Ginet, Françoise Michel, Laetitia Villon, Jean-Paul Cristol, Claude Colette, Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes JAMA. ,vol. 295, pp. 1681- 1687 ,(2006) , 10.1001/JAMA.295.14.1681